New Zealand markets open in 5 hours 52 minutes

BIIB220819P00290000

OPR - OPR Delayed price. Currency in USD
Add to watchlist
80.710.00 (0.00%)
As of 12:00AM EDT. Market open.
Full screen
Previous close80.71
OpenN/A
Bid84.50
Ask90.60
StrikeN/A
Expiry date2022-08-19
Day's range80.71 - 80.71
Contract rangeN/A
VolumeN/A
Open interest5
  • Yahoo Finance Video

    Health care bill ‘most aggressive action’ on drug pricing: Analyst

    Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.

  • Motley Fool

    Good News for Retirees: Lower Medicare Part B Premiums Could Be Coming

    Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.

  • GlobeNewswire

    The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

    Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpointBiogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ studies and plans to initiate a pivotal study in CLE later this yearBiogen is advancing two lupus therapies in Phase 3 trials to address this chronic autoimmune disease CAMBRIDGE, Mass., July 28, 2022 (